Cancer

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-makingStrong track record of successful clinical…

3 months ago

CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1)…

3 months ago

Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement

TORONTO, ON / ACCESSWIRE / April 24, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF)(FRA:TTX), a clinical stage…

3 months ago

Spago Nanomedical Reports Favorable Data in Breast Cancer Model with Tumorad

LUND, SWEDEN / ACCESSWIRE / April 24, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today data from…

3 months ago

Angle PLC Announces New Commercial Agreement with AstraZeneca

ANGLE signs agreement to tailor existing Parsortix-based DNA damage response assay for use in pharmaceutical R&D GUILDFORD, SURREY / ACCESSWIRE…

3 months ago

Anne Arundel Dermatology Adds Intelligent Scheduling Capabilities to Improve Patient Experience

Relatient’s centralized scheduling platform and patient self-scheduling tools will enhance patient access while streamlining staff workflowsATLANTA--(BUSINESS WIRE)--#DashEngage--Anne Arundel Dermatology (AADerm),…

3 months ago

CNS Pharmaceuticals to Present at the LSX World Congress 2024

Presentation on Monday, April 29th at 4:15 PM (GMT+1)HOUSTON, TX / ACCESSWIRE / April 23, 2024 / CNS Pharmaceuticals, Inc.…

3 months ago

Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy

Provides Further Evidence of Multiple Opportunities for Development of the FABP Inhibitor Platform in Cancer & Other Serious ConditionsSOLANA BEACH,…

3 months ago

Defence’s AccuTOX Anti-Cancer ARM-002 Vaccine Exhibits Potent Antigen Presentation

Vancouver, British Columbia--(Newsfile Corp. - April 23, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or…

3 months ago